Keywords Biomarkers; Cerebrovascular; Clinical trials; Genetics; Neuroimaging; Neuropathology; Neuropsychology Two decades ago, if charged with the task of indicating future directions for research into Down syndrome (DS) and Alzheimer’s disease…
Clinical trials—An overview Clinical trials generally evaluate therapeutics in four phases before a new drug can be approved for use in the clinic. Each of these phases has a different…
Introduction Down syndrome (DS) is the most common genetic cause of intellectual disability, affecting approximately 16 per 10,000 live births in the United States [1–3] (see Chapter 1). DS is…
Introduction As mentioned in Chapter 1, people with Down syndrome (DS) develop Alzheimer’s disease (AD) neuropathology by 40 years of age (Chapter 2), and in most, dementia develops in their…
Acknowledgments This work was supported by National Institutes of Health grants: P01 HD035897, U54 HD079123, U01 AG051412, and R01 AG014673 as well as funds from the New York State Office…
Alzheimer’s disease in adults with Down syndrome As described in Chapter 1, Down syndrome (DS) is one of the most common genetic diseases. Adults with DS carry three copies of…
Epidemiology While the prevalence rates of physical health conditions, and in particular Alzheimer’s disease (AD), in people with Down syndrome (DS) have been extensively researched [1, 2] (also see Chapters…
Chapter 13: Contributions of the neurological examination to the diagnosis of dementia in Down syndrome Ira T. Lotta,*; H. Diana Rosasb,,c; Florence Laib; Shahid Zamand a Department of Pediatrics, School of…
Proteomic and metabolomic methodologies In the general AD population, proteomic and metabolomic studies are under close scrutiny as inconsistency in outcomes and variability in preanalytic methods (sample collection, processing, storage,…
Prevalence The prevalence of Down syndrome (DS) in the United States is believed to be about 8.27 per 10,000 persons. Based upon birth prevalence and death certificate data the US…
